E. Abdalla, R. Adam, A. Bilchik, D. Jaeck, J. Vauthey et al., Improving resectability of hepatic colorectal metastases: expert consensus statement, Ann Surg Oncol, vol.13, issue.10, pp.1271-80, 2006.

Z. Amoura, J. C. Piette, H. Chabre, P. Cacoub, T. Papo et al., Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity, Arthritis Rheum, vol.40, issue.12, pp.2217-2242, 1997.

H. J. Andreyev, A. R. Norman, D. Cunningham, J. Oates, B. R. Dix et al., Kirsten ras mutations in patients with colorectal cancer: the « RASCAL II » study, Br J Cancer, vol.85, issue.5, pp.692-698, 2001.

, Association canadienne du cancer colorectal. Comprendre le cancer coloreactal

. Disponible,

J. Baret, Y. Beck, I. Billas-massobrio, D. Moras, and A. D. Griffiths, Quantitative Cell-Based Reporter Gene Assays Using Droplet-Based Microfluidics, Chem Biol, vol.17, issue.5, pp.528-564, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02148764

S. E. Bates and D. L. Longo, Tumor markers: value and limitations in the management of cancer patients, Cancer Treat Rev, vol.12, issue.3, pp.163-207, 1985.

V. Bazan, L. Bruno, C. Augello, A. V. Calò, V. Corsale et al., Molecular Detection Of TP53, KiRas And P16ink4a Promoter Methylation In Plasma Of Patient s With Colorectal Cancer And Its Association With Prognosis

, Prospective Study. Ann Oncol, vol.17, issue.7, pp.84-90, 2006.

B. Chibaudel and C. T. , Therapeutic Strategy In Unresectable Metastatic Colorectal Cancer: An Updated Review, Ther Adv Med Oncol, vol.7, issue.3, 2015.

J. Bennouna, J. Sastre, D. Arnold, P. Österlund, R. Greil et al., Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, vol.14, issue.1, pp.29-37, 2013.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014.

F. Bibeau, H. Frugier, A. Denouel, J. Sabourin, and F. Boissiere-michot, Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view, Bull Cancer, vol.96, pp.15-22, 2009.

P. Boyle and J. S. Langman, ABC of colorectal cancer: Epidemiology. BMJ, vol.321, issue.7264, pp.805-813, 2000.

S. Breitbach, S. Tug, and P. Simon, Circulating cell-free DNA: an up-coming molecular marker in exercise physiology, Sports Med, vol.42, issue.7, pp.565-86, 2012.

C. Dreyer and É. Raymond, Sandrine Faivre. PI3K / AKT / Mtor Signalling Pathway. Cancéro Dig

, Centers for Disease Control and Prevention & National Cancer Institute; Cancer Statistics Working Group

G. S. Atlanta, Department of Health and Human Services

M. Chaix, J. Vincent, V. Lorgis, and F. Ghiringhelli, FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer, Oncology, vol.87, issue.3, pp.148-58, 2014.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, issue.26, pp.2507-2523, 2011.

C. H. Chau, O. Rixe, H. Mcleod, and W. D. Figg, Validation of analytic methods for biomarkers used in drug development, Clin Cancer Res, vol.14, pp.5967-76, 2008.

R. Chiu, R. Akolekar, Y. Zheng, T. Y. Leung, H. Sun et al., Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study

, BMJ, vol.342, p.7401, 2011.

J. Choi, C. F. Reich, and D. S. Pisetsky, The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells, Immunology, vol.115, issue.1, pp.55-62, 2005.

E. Day, P. H. Dear, and F. Mccaughan, Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine, Methods, vol.59, issue.1, pp.101-108, 2013.

S. Dawson, D. Tsui, M. Murtaza, H. Biggs, O. M. Rueda et al., Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, N Engl J Med, vol.368, issue.13, pp.1199-209, 2013.

W. De-roock, B. Biesmans, D. Schutter, J. Tejpar, and S. , Clinical biomarkers in oncology: focus on colorectal cancer, Mol Diagn Ther, vol.13, issue.2, pp.103-117, 2009.

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, vol.11, issue.8, pp.753-62, 2010.

A. Didelot, S. K. Kotsopoulos, A. Lupo, D. Pekin, X. Li et al., Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, issue.5, pp.815-838, 2013.

A. Didelot, Place de l'ADN tumoral circulant dans la prise en charge des patients atteints d'une tumeur pulmonaire : impact pronostique et suivi dynamique de l'évolution des altérations génétiques au cours du traitement. Mémoire de l'École Pratique des Hautes Études, p.124, 2017.

F. Diehl, M. Li, D. Dressman, Y. He, D. Shen et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci USA, vol.102, issue.45, pp.16368-73, 2005.

F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman et al., Circulating mutant DNA to assess tumor dynamics, Nat Med, vol.14, issue.9, pp.985-90, 2008.
DOI : 10.1038/nm.1789

URL : http://europepmc.org/articles/pmc2820391?pdf=render

R. Dienstmann, L. Vermeulen, J. Guinney, S. Kopetz, S. Tejpar et al., Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer, Nat Rev Cancer, 2017.

D. Dressman, H. Yan, G. Traverso, K. W. Kinzler, and B. Vogelstein, Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations, Proc Natl Acad Sci USA, vol.100, issue.15, pp.8817-8839, 2003.

J. Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes et al., Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Ann Oncol, vol.25, issue.7, pp.1346-55, 2014.

A. Duval and R. Hamelin, Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability, Cancer Res, vol.62, issue.9, pp.2447-54, 2002.

M. Esteller, S. González, R. A. Risques, E. Marcuello, R. Mangues et al.,

, Aberrations Confer Poor Prognosis In Human Colorectal Cancer, J Clin Oncol, vol.19, issue.2, pp.299-304, 2001.

A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini et al., Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest, J Clin Oncol, vol.25, issue.13, pp.1670-1676, 2007.

M. Fleischhacker and B. Schmidt, Circulating nucleic acids (CNAs) and cancer-a survey, Biochim Biophys Acta, vol.1775, issue.1, pp.181-232, 2007.

F. Moulière, Etude de la structure et de l'origine des ADN circulants : application à la mise au point d'un test de détection des mutations KRAS et BRAF dans le cancer colorectal. Université de Montpellier 2, Sciences Chimiques et Biologiques pour la Santé, p.123, 2012.

, Physical Activity, and the Prevention of Cancer. World Cancer Research Fund and American Institute for Cancer Research: A Global Perspective, 2007.

, Institut National Du Cancer .Les cancers en France en 2014-L'essentiel des faits et chiffres

. Disponible,

M. Galeazzi, G. Morozzi, M. Piccini, J. Chen, F. Bellisai et al., Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders, Autoimmun Rev, vol.2, issue.1, pp.50-55, 2003.

S. Geiger, S. Holdenrieder, P. Stieber, G. F. Hamann, R. Bruening et al., Nucleosomes In Serum Of Patients With Early Cerebral Stroke. Cerebrovasc Dis, vol.21, issue.1, pp.32-39, 2006.

B. J. Giantonio, P. J. Catalano, N. J. Meropol, O. Dwyer, P. J. Mitchell et al., Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, vol.25, issue.12, pp.1539-1583, 2007.

E. Gormally, E. Caboux, P. Vineis, and P. Hainaut, Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance, Mutat Res, vol.635, issue.2-3, pp.105-122, 2007.

A. Grothey and D. Sargent, Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line, J Clin Oncol, vol.23, issue.36, pp.9441-9443, 2005.

A. Grothey, E. Van-cutsem, A. Sobrero, S. Siena, A. Falcone et al., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, vol.381, issue.9863, pp.303-315, 2013.

A. Harlé, Marqueurs de réponse aux thérapies ciblées et personnalisation thérapeutique dans les cancers colorectaux métastatiques, p.152, 2014.

K. A. Heyries, C. Tropini, M. Vaninsberghe, C. Doolin, O. I. Petriv et al.,

, Nat Meth, vol.8, issue.8, pp.649-51, 2011.

S. Holdenrieder, P. Stieber, T. Förg, M. Kühl, L. Schulz et al., Apoptosis In Serum Of Patients With Solid Tumours. Anticancer Res, vol.19, issue.4A, pp.2721-2725, 1999.

M. Huang, H. Liu, Y. Chang, J. Huang, J. Wang et al., Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array, Journal of Translational Medicine, vol.12, p.147, 2014.

, Institut National Du Cancer .Les cancers en France en 2014-L'essentiel des faits et chiffres

. Disponible,

Y. Ionov, M. A. Peinado, S. Malkhosyan, D. Shibata, and M. Perucho, Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis, Nature, 1993.

J. Jackson-thompson, A. F. German, R. R. Lai, S. Friedman, and C. , Descriptive epidemiology of colorectal cancer in the United States, Cancer, vol.107, issue.5, pp.1103-1114, 1998.

S. Jahr, H. Hentze, S. Englisch, D. Hardt, F. O. Fackelmayer et al., DNA Fragments In The Blood Plasma Of Cancer Patients: Quantitations And Evidence For Their Origin From Apoptotic And Necrotic Cells, Cancer Res, vol.61, issue.4, pp.1659-65, 2001.

R. Jatin and H. Kenneth, Molecular Mechanisms of Colorectal Carcinogenesis. In Molecular Pathogenesis of Colorectal Cancer, pp.25-65, 2013.

A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, Cancer Journal for Clinicians, vol.61, issue.2, pp.69-90, 2011.

P. Jiang, C. Chan, K. Chan, S. H. Cheng, J. Wong et al., Lengthening And Shortening Of Plasma DNA In Hepatocellular Carcinoma Patients, Proc Natl Acad Sci USA, vol.112, issue.11, pp.1317-1342, 2015.

P. A. Jones and S. B. Baylin, The Fundamental Role Of Epigenetic Events In Cancer, Nat Rev Genet, 2002.

A. Jong, H. Morreau, F. Nagengast, E. Mathus-vliegen, J. Kleibeuker et al., Prevalence of adenomas among young individuals at average risk for colorectal cancer, Am J Gastroenterol, 2005.

K. Jung, M. Fleischhacker, and A. Rabien, Cell-Free DNA In The Blood As A Solid Tumor Biomarker-A Critical Appraisal Of The Literature, Clin Chim Acta, vol.411, pp.1611-1635, 2010.

K. Taniguchi, J. Uchida, K. Nishino, T. Kumagai, T. Okuyama et al., Quantitative Detection Of EGFR Mutations In Circulating Tumor DNA Derived From Lung Adenocarcinomas. Clinical Cancer, pp.11-1712, 2011.

S. M. Keyse, Dual-Specificity MAP Kinase Phosphatases (Mkps) And Cancer, Cancer Metastasis Rev, vol.27, issue.2, pp.253-61, 2008.
DOI : 10.1007/s10555-008-9123-1

P. P. Laktionov, S. N. Tamkovich, E. Y. Rykova, O. E. Bryzgunova, A. V. Starikov et al.,

, Extracellular circulating nucleic acids in human plasma in health and disease, Nucleosides Nucleotides Nucleic Acids, vol.23, issue.6-7, pp.879-83, 2004.

T. Lecomte, N. Ceze, E. Dorval, and P. Laurent-puig, Circulating free tumor DNA and colorectal cancer
DOI : 10.1016/j.gcb.2009.04.015

URL : https://hal.archives-ouvertes.fr/hal-00618040

, Gastroenterol Clin Biol, vol.34, issue.12, pp.662-81, 2010.

S. A. Leon, B. Shapiro, D. M. Sklaroff, and M. J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, issue.3, pp.646-50, 1977.

A. Lièvre and . Laurent-puig, La voie de signalisation RAS/MAPK RAS/MAPK signaling pathway. Cancéro dig, vol.2, pp.1-2010

A. Lièvre, H. Blons, and P. Laurent-puig, Oncogenic mutations as predictive factors in colorectal cancer, Oncogene, vol.29, issue.21, pp.3033-3076, 2010.

A. Lièvre, J. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, issue.8, pp.3992-3997, 2006.

A. Lièvre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, vol.26, issue.3, pp.374-383, 2008.

S. T. Ligthart, F. Coumans, G. Attard, A. M. Cassidy, J. S. Bono et al., Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival, PLoS ONE, vol.6, issue.11, p.27419, 2011.

H. Linardou, I. J. Dahabreh, D. Bafaloukos, P. Kosmidis, and S. Murray, Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC, Nat Rev Clin Oncol, vol.6, issue.6, pp.352-66, 2009.

Y. M. Lo, N. Corbetta, P. F. Chamberlain, V. Rai, I. L. Sargent et al., Presence of fetal DNA in maternal plasma and serum, Lancet, vol.350, issue.9076, pp.485-492, 1997.

Y. M. Lo, J. Zhang, T. N. Leung, T. K. Lau, A. M. Chang et al., Rapid clearance of fetal DNA from maternal plasma, Am J Hum Genet, vol.64, issue.1, pp.218-242, 1999.

M. Macaluso, G. Russo, C. Cinti, V. Bazan, N. Gebbia et al., Ras family genes: An interesting link between cell cycle and cancer, J Cell Physiol, vol.192, issue.2, pp.125-155, 2002.
DOI : 10.1002/jcp.10109

S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan et al., Detection of Mutations in EGFR in Circulating Lung-Cancer Cells, N Engl J Med, vol.359, issue.4, pp.366-77, 2008.

P. Mandel and P. Metais, Les Acides Nucléiques Du Plasma Sanguin Chez L'homme, C R Seances Soc Biol Fil, vol.142, issue.3-4, pp.241-244, 1948.

S. D. Markowitz and M. M. Bertagnolli, Molecular origins of cancer: Molecular basis of colorectal cancer, N Engl J Med, vol.361, issue.25, pp.2449-60, 2009.

G. Marwan and . Fakih, CEA Monitoring in Colorectal Cancer | Cancer Network, 2016.

J. Mendelsohn and J. Baselga, Epidermal growth factor receptor targeting in cancer, Semin Oncol, 2006.

J. Merlin, Biomarqueurs Moléculaires en Oncologie, p.175, 2014.

M. P. Morelli, M. J. Overman, A. Dasari, S. Kazmi, T. Mazard et al., Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to antiEGFR treatment, Ann Oncol, vol.26, issue.4, pp.731-737, 2015.

F. Mouliere, E. Messaoudi, S. Gongora, C. Guedj, A. et al., Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load, Transl Oncol, vol.6, issue.3, pp.319-347, 2013.
DOI : 10.1593/tlo.12445

URL : https://hal.archives-ouvertes.fr/hal-00872683

F. Mouliere and N. Rosenfeld, Circulating Tumor-Derived DNA Is Shorter Than Somatic DNA In Plasma

, Proc Natl Acad Sci USA, vol.112, issue.11, pp.3178-3187, 2015.

N. Umetani and A. , Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum, J Clin Oncol, vol.24, issue.26, pp.4270-4276, 2006.

A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. Eclov et al., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, issue.5, pp.548-54, 2014.
DOI : 10.1038/nm.3519

URL : http://europepmc.org/articles/pmc4016134?pdf=render

M. E. Norton, B. Jacobsson, G. K. Swamy, L. C. Laurent, A. C. Ranzini et al., Cell-free DNA Analysis for Noninvasive Examination of Trisomy, N Engl J Med, vol.372, issue.17, pp.1589-97, 2015.

C. M. Nutting, S. Cancer-;-v-t-devita, S. Hellman, and . Rosenburg, Principles & practice of oncology (6th edn), vol.75, pp.567-567, 2001.

K. Perez-toralla, D. Pekin, J. Bartolo, F. Garlan, P. Nizard et al., PCR Digitale En Micro-Compartiments-I. Détection Sensible De Séquences D'acides Nucléiques Rares, Med Sci, vol.31, issue.1, pp.84-92, 2015.
DOI : 10.1051/medsci/20153101017

URL : https://hal.archives-ouvertes.fr/hal-01140226

D. Pekin, Y. Skhiri, J. Baret, L. Corre, D. Mazutis et al., Quantitative And Sensitive Detection Of Rare Mutations Using Droplet-Based Microfluidics, Lab Chip, vol.11, issue.13, pp.2156-66, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02148770

D. L. Peters, P. J. Pretorius, and . Origin, Translocation And Destination Of Extracellular Occurring DNA-A New Paradigm In Genetic Behaviour, Clin Chim Acta, vol.412, pp.806-817, 2011.

F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi, V. Lonati et al., FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials, Clin Colorectal Cancer, vol.12, issue.3, pp.145-51, 2013.

M. J. Pillaire, G. Villani, J. S. Hoffmann, A. M. Mazard, and M. Defais, Characterization and localization of cisdiamminedichloro-platinum(II) adducts on a purified oligonucleotide containing the codons 12 and 13 of H-ras proto-oncogene, Nucleic Acids Res, vol.20, issue.24, pp.6473-6482, 1992.

M. S. Pino and D. C. Chung, The chromosomal instability pathway in colon cancer, Gastroenterology, 2010.

D. Pietrasz, N. Pécuchet, E. Fabre, H. Blons, L. Chevalier et al., Quel Avenir Pour L'adn Tumoral Circulant ? État Des Lieux Et Perspectives Dans Les Cancers Colorectaux, Pulmonaires Non A Petites Cellules Et Pancréatiques, Bull Cancer, vol.103, issue.1, pp.55-65, 2016.

H. Prenen, D. Schutter, J. Jacobs, B. De-roock, W. Biesmans et al., PIK3CA Mutations Are Not A Major Determinant Of Resistance To The Epidermal Growth Factor Receptor Inhibitor Cetuximab In Metastatic Colorectal Cancer, Clin Cancer Res, vol.15, issue.9, pp.3184-3192, 2009.

G. Pöschl and H. Seitz, Alcohol and cancer. Alcohol Alcohol, vol.39, issue.3, pp.155-65, 2004.

A. Sartore-bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti et al., PIK3CA Mutations In Colorectal Cancer Are Associated With Clinical Resistance To EGFR-Targeted Monoclonal Antibodies, Cancer Res, vol.69, issue.5, pp.1851-1858, 2009.

M. W. Schmitt, S. R. Kennedy, J. J. Salk, E. J. Fox, J. B. Hiatt et al., Detection Of Ultra-Rare Mutations By Next-Generation Sequencing, Proc Natl Acad Sci USA, vol.109, issue.36, pp.14508-14521, 2012.

W. A. Schulz, C. Steinhoff, and A. R. Florl, Methylation Of Endogenous Human Retroelements In Health And Disease, Curr Top Microbiol Immunol, vol.310, pp.211-50, 2006.

H. Schwarzenbach, D. Hoon, and K. Pantel, Cell-Free Nucleic Acids As Biomarkers In Cancer Patients, Nat Rev Cancer, vol.11, issue.6, pp.426-463, 2011.

R. Siegel, K. Miller, and A. Jemal, Cancer statistics, Cancer Journal for Clinicians, vol.65, issue.1, pp.5-29, 2015.
DOI : 10.3322/caac.21332

A. B. Singh and R. C. Harris, Autocrine, paracrine and juxtacrine signaling by EGFR ligands, Cell Signal, vol.17, issue.10, pp.1183-93, 2005.
DOI : 10.1016/j.cellsig.2005.03.026

J. Shia, Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome, J Mol Diagn, vol.10, issue.4, pp.293-300, 2008.

L. Sobin and C. C. Compton, TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer, Cancer, 2010.

G. D. Sorenson, D. M. Pribish, F. H. Valone, V. A. Memoli, D. J. Bzik et al., Soluble Normal And Mutated DNA Sequences From Single-Copy Genes In Human Blood, Cancer Epidemiol Biomarkers Prev

G. D. Sorenson, Detection Of Mutated KRAS2 Sequences As Tumor Markers In Plasma/Serum Of Patients With Gastrointestinal Cancer, Clin Cancer Res, vol.6, issue.6, pp.2129-2166, 2000.

J. Souglakos, N. Androulakis, K. Syrigos, A. Polyzos, N. Ziras et al., FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG), Br J Cancer, vol.94, issue.6, pp.798-805, 2006.

G. Sozzi, D. Conte, L. Mariani, S. L. Vullo, R. L. Lombardo et al., Analysis Of Circulating Tumor DNA In Plasma At Diagnosis And During Follow-Up Of Lung Cancer Patients, Cancer Res, 2001.

K. Spindler, A. L. Appelt, N. Pallisgaard, R. F. Andersen, I. Brandslund et al., Cell-Free DNA In Healthy Individuals, Noncancerous Disease And Strong Prognostic Value In Colorectal Cancer, Int J Cancer, vol.135, issue.12, pp.2984-91, 2014.

M. Stroun, P. Anker, P. Maurice, J. Lyautey, C. Lederrey et al., Neoplastic Characteristics Of The DNA Found In The Plasma Of Cancer Patients, Oncology, vol.46, issue.5, pp.318-340, 1989.

M. Stroun, P. Anker, and L. Ledoux, Fate Of DNA Of Bacterial Origin After Its Migration Into Plants, Arch Int Physiol Biochim, vol.74, issue.5, pp.935-942, 1966.

P. J. Sykes, S. H. Neoh, M. J. Brisco, E. Hughes, J. Condon et al., Quantitation Of Targets For PCR By Use Of Limiting Dilution, Biotechniques, vol.13, issue.3, pp.444-453, 1992.

D. S. Tawfik and A. D. Griffiths, Man-Made Cell-Like Compartments For Molecular Evolution, Nat Biotech

S. Teh, R. Lin, L. Hung, and A. P. Lee, Droplet Microfluidics. Lab Chip, vol.8, issue.2, pp.198-220, 2008.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex Picodroplet Digital PCR To Detect KRAS Mutations In Circulating DNA From The Plasma Of Colorectal Cancer Patients

, Clin Chem, vol.59, issue.12, pp.1722-1753, 2013.

S. N. Tamkovich, A. V. Cherepanova, E. V. Kolesnikova, E. Y. Rykova, D. V. Pyshnyi et al.,

, Circulating DNA And Dnase Activity In Human Blood. Ann N Y Acad Sci, vol.1075, pp.191-197, 2006.

P. Tangkijvanich, N. Hourpai, P. Rattanatanyong, N. Wisedopas, V. Mahachai et al., Serum LINE-1 Hypomethylation As A Potential Prognostic Marker For Hepatocellular Carcinoma, Clinica Chimica Acta, vol.379, issue.1-2, pp.127-160, 2007.

A. R. Thierry, F. Mouliere, E. Messaoudi, S. Mollevi, C. Lopez-crapez et al., Clinical Validation Of The Detection Of KRAS And BRAF Mutations From Circulating Tumor DNA, Nat Med, 2014.

C. Therkildsen, T. K. Bergmann, T. Henrichsen-schnack, S. Ladelund, and M. Nilbert, The Predictive Value Of KRAS, NRAS, BRAF, PIK3CA And PTEN For Anti-EGFR Treatment In Metastatic Colorectal Cancer: A Systematic Review And Meta-Analysis, Acta Oncol, vol.53, issue.7, pp.852-64, 2014.

S. N. Thibodeau, G. Bren, and D. Schaid, Microsatellite instability in cancer of the proximal colon, Science, vol.260, issue.5109, pp.816-825, 1993.

C. Trevisiol, D. Fabio, F. Nascimbeni, R. Peloso, L. Salbe et al., Prognostic Value Of Circulating KRAS2 Gene Mutations In Colorectal Cancer With Distant Metastases, Int J Biol Markers, vol.21, issue.4, pp.223-231, 2006.

C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh et al., FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

, J Clin Oncol, vol.22, issue.2, pp.229-266, 2004.

U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber et al., Irinotecan in the treatment of colorectal cancer: clinical overview, J Clin Oncol, vol.19, issue.5, pp.1501-1519, 2001.

E. Van-cutsem, C. Köhne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 2009.

E. Van-cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausová et al., Addition Of Aflibercept To Fluorouracil, Leucovorin, And Irinotecan Improves Survival In A Phase III Randomized Trial In Patients With Metastatic Colorectal Cancer Previously Treated With An Oxaliplatin-Based Regimen, J Clin Oncol, vol.30, issue.28, pp.3499-506, 2012.

E. Van-cutsem, C. Köhne, I. Láng, G. Folprecht, M. P. Nowacki et al., Cetuximab Plus Irinotecan, Fluorouracil, And Leucovorin As First-Line Treatment For Metastatic Colorectal Cancer: Voelkerding KV, Dames S, Durtschi JD. Next Generation Sequencing For Clinical DiagnosticsPrinciples And Application To Targeted Resequencing For Hypertrophic Cardiomyopathy, J Mol Diagn, vol.12, issue.5, pp.539-51, 2010.

, Updated Analysis Of Overall Survival According To Tumor KRAS And BRAF Mutation Status, J Clin Oncol, vol.29, issue.15, pp.2011-2020, 2011.

J. Wang, J. Hsieh, C. Lu, F. Yu, J. Wu et al., The Differentially Mutational Spectra Of The APC, K-Ras, And P53 Genes In Sporadic Colorectal Cancers From Taiwanese Patients

, Hepatogastroenterology, vol.54, issue.80, pp.2259-65, 2007.

B. G. Wang, H. Huang, Y. Chen, R. E. Bristow, K. Kassauei et al., Increased Plasma DNA Integrity In Cancer Patients, Cancer Res, vol.63, issue.14, pp.3966-3974, 2003.

W. C. Willett, Diet And Cancer: An Evolving Picture, JAMA, vol.293, issue.2, pp.233-237, 2005.

A. B. Wilmink, Overview Of The Epidemiology Of Colorectal Cancer, Dis Colon Rectum, 1997.

, World Health Organization. Estimation Cancer Incidence Mortality And Prevalence Worlwide, 2012.

D. Sur,

, World Health Organization. Colorectum Cancer Statistics In India, 2012.

D. Sur,

L. Yen, Y. Yeh, C. Chen, H. Wang, H. Tsai et al., Detection Of KRAS Oncogene In Peripheral Blood As A Predictor Of The Response To Cetuximab Plus Chemotherapy In Patients With Metastatic Colorectal Cancer, Clin Cancer Res, vol.15, issue.13, pp.4508-4521, 2009.

M. Korabecna, S. Opatrna, J. Wirth, K. Rulcova, J. Eiselt et al., Cell-Free Plasma DNA During Peritoneal Dialysis And Hemodialysis And In Patients With Chronic Kidney Disease, Ann N Y Acad Sci, vol.1137, pp.296-301, 2008.

Q. Zhong, S. Bhattacharya, S. Kotsopoulos, J. Olson, V. Taly et al., Multiplex Digital PCR: Breaking The One Target Per Color Barrier Of Quantitative PCR, Lab Chip, vol.11, issue.13, pp.2167-74, 2011.

S. Zeerleder, The Struggle To Detect Circulating DNA, Crit Care, vol.10, issue.3, p.142, 2006.

A. Zisman, A. Nickolov, R. Brand, A. Gorchow, and H. Roy, Associations Between The Age At Diagnosis And Location Of Colorectal Cancer And The Use Of Alcohol And Tobacco: Implications For Screening, Arch Intern Med, vol.166, issue.6, pp.629-663, 2006.

I. Zlobec and A. Lugli, Prognostic And Predictive Factors In Colorectal Cancer, J Clin Pathol, 2008.

, La classification du CCR Annexe 2 : Représentation schématique de différents types de PCR digitale Annexe 3 : Les étapes principales de NGS Annexe 4 : Comparaison des technologies de séquençage à haut débit Annexe 5 : Les principales caractéristiques des billes magnétiques, vol.1

, ~ slUff'f (v/'1) in 10 mM Tris with 0.09'b sodium azidc:, pH &.O Recombinant itteptavldu\ covatc:ntly cou pied to silica·bascd bc:ldJ 10 ~

C. 'llpocity, ,. , ,. , ~. .. , and .. .. , Y~"f°" dw "'°Ptttitt ef '"" #!d!Wl111rl r«M i1tW!f "* Up to 6 pmolcs oligonuclC01idr pcr vL of bf:ad susptnsion N~: ~dlilf (O,PCK'ltv ls "-11/dy "lll'led 10 lflOll'C'Uk, Up IO 0.65119 llooeon,4atrd IM pa l'l d bud-Up .. 1.0"' boolon,4atrd lg0

, · f\u&\Uboe'll Stttptnidin M'9ftdÎC ladl ltt for munfl UK canly. Thry att not fot ust: in dilgnOl.tit prooedu~ Disposai Collrcl and dispose of uK'd N lcri11l 1cto1dlng to 111 applicable ln1rmational. fcdcral, statr, and local rrgulatlons

, Safety Data Sheet Slftt

, Oltl Shttts CSOS) l fC IVlibtlk Of'I Ol,lf wtb litt. Go to www mi, lll:J!O!!.C'M! Md auu "°"' a Wogw: numbtr 11111 tht wMh boL M Product Ordtring Information

Q. !y/pk, C. No, and . Pu,

. Ma and . .. Kticklds, Sia.tAOO, vol.1

!. .. Ili,

_. , Notice lhe inrofml llon ln lhis document ls suti;ccl Io cha~c whtloul notice arwl should not bt construed as? commltrnc:nt by Milliporc: Corpor1don ("Milliporc1 or an affi liatc:. Ncittlcr Milllport Cotpor1tiOl'I nat 1nv or iu affiliatH 111umc:s rc:,poMlt>Hlty ror ? nv crf

, Technlcal Assistanct fol' MCM'C ~fom'l.IÔOf\ mntact tht Milipoft' offitt Mlttll ~ t

, 90 to out web site: at www.millleors tom'offim for up-1<~

, dite wortd'wlde COf\tact in.formation. You ca.n elso vilit the ttth